Just what the world needs, more ways to screw up people’s mental processes. Caitlin Johnstone is probably right, though; the corporations will figure out a way to make a lot of money off psychedelics, and who cares what they’ll do to people’s ability to think. From Johnstone at caitlinjohnstone.com:
“Money has begun flowing into companies intending to monetize psychedelic therapy as new research has increasingly shown that blowing one’s mind can alter it for the better,” reads a new article for the Los Angeles Times titled “Money is pouring into psychedelics. Meet the mystical hedge fund investor bankrolling the boom.”
“This scientific and commercial excitement rests on research showing that psychedelics can supercharge mental health treatment for PTSD, depression, anxiety, addiction, and other chronic ailments of the mind, enabling patients to dive deep, confront their traumas and — a rarity for mental illnesses — return healed,” the article reads. “That goes for synthetic chemicals such as MDMA and ketamine as well as plant-derived drugs such as psilocybin (the active ingredient in magic mushrooms), the South American plant brew ayahuasca, and the West African root-derived substance iboga.”
LA Times’ Sam Dean shares the personal journey of hedge fund investor Sa’ad Shah and his involvement in what has become a multibillion-dollar psychedelics industry long before even the legal infrastructure necessary for such companies to turn a profit is in place. We learn of Shah’s experience with ayahuasca, his interest in mystical traditions and personal growth, and his conviction in the shift that has for the last few years been known as the psychedelic renaissance.
And then, about halfway down the article, we get to the actual meat of the matter:
“Shah welcomes big pharma and big institutions to enter the fray in the interest of spreading the chemical gospel far and wide. He sees the financial and therapeutic potential for psychedelics not in the cannabis model, which would make psychedelics broadly available for retail purchase, but in the pharmaceutical mode — psychedelics as prescribed drugs, with patent rights, administered in medical settings.”